Study of Olive Leaf Extracts to Help Control Type 2 Diabetes in Adults

What this Trial Is About

Researchers are evaluating the effects of olive leaf extracts atherolive on adults with type 2 diabetes. This study is conducted in emergency departments and external endocrinology and diabetology consultations at two hospitals. The trial compares atherolive to a placebo to better understand its impact on blood sugar control and related health markers. Participants will be randomly assigned to receive either atherolive or a placebo, both given as a 400 mg dose once daily for three months. Before treatment, patients undergo biological assessments including lipid profiles, blood sugar, creatinine levels, HbA1c for diabetics, and inflammatory markers like C-reactive protein. Continuous blood glucose monitoring using an iPro device is performed at the start to measure blood sugar variability. During the study, researchers will track continuous glucose monitoring results and Hemoglobin A1c levels over 90 days. Additional outcomes include changes in lipid balance and hospitalizations due to cardiovascular disease or adverse effects. Participants will be monitored for three months, with assessments to evaluate treatment effects and safety throughout.

Olive Leaf Extracts in the Control of Diabet